Adding everolimus to fulvestrant improved outcomes for postm
Progression-free survival was more than doubled for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy by adding everolimus (Afinitor) to treatment with the endocrine therapeutic fulvestrant (Faslodex), according to data from the PrECOG 0102 phase II clinical trial presented at the 2016 San Antonio Breast Cancer Symposium, held Dec. 6–10....

http://medicalxpress.com/news/2016-12-adding-everolimus-fulvestrant-outcomes-postmenopausal.html
Like
Comment
Share